Impax Laboratories Inc

Impax Laboratories — Q3 2017 Earnings Presentation

22 slides from Impax Laboratories's earnings presentation, Nov 9, 2017

  1. Slide 1: Third Quarter 2017 Results and Business Update

    1 Third Quarter 2017 Results and Business Update November 9, 2017

  2. Slide 2: Cautionary Statement Regarding Forward Looking Statements

    2 Impax Cautionary Statement Regarding Forward Looking Statements "Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: To the extent any statements made in this presentation contain information that is not historical; these statements are forward-looking in nature and

  3. Slide 3: Paul Bisaro, President & CEO

    3 Paul Bisaro President & CEO

  4. Slide 4: Focused on Improving Profitability and Earnings

    4 Focused on Improving Profitability and Earnings $228 $202 $206 3Q16 2Q17 3Q17 $59 $39 $46 3Q16 2Q17 3Q17 $0.37 $0.18 $0.23 3Q16 2Q17 3Q17 Revenues $ millions Adjusted EBITDA $ millions Adjusted EPS Refer to the GAAP to non-GAAP reconciliation tables in the appendix for a reconciliation of non-GAAP

  5. Slide 5: Third Quarter 2017 Business Update

    5 Third Quarter 2017 Business Update Quarter Results  3Q17 vs. 3Q16 – Revenue down 14%  Driven by lower pricing (-18%) and partially offset by increased volumes  Excluding epinephrine auto-injector and gAdderall XR®, 3Q17 pricing across generic products was down ~7% to 9%  3Q17 vs. 2Q17 – Revenu

  6. Slide 6: IPX203: Positive Outcome of Phase 2b Study

    6 0 10 20 30 40 50 60 70 80 0.5 h 1 h 1.5 h 2 hP ro p ort io n o f S u b je c ts A c h ie v in g De fi n e d Red u c ti o n i n O ff T im e Reduction in Off Time from Baseline IPX203 IR CD-LD 0 10 20 30 40 50 60 7-point 13-point P ro p ort io n o f S u b je c ts A c h ie v in g S p e c if ie d I m p

  7. Slide 7: Accelerated Progress on Consolidation and Improvement Plan

    7 2017 Initiatives Original Timing Updated Timing Consolidation of all generic R&D to Hayward, CA Completed mid-2017 Completed on-time Closure of Middlesex packaging site Completion by end of 1Q18 Completion by end of 2017 Rationalizing generic portfolio to eliminate low-value products Completion by

  8. Slide 8: A Strategic Combination for Long-Term Growth

    8 A Strategic Combination for Long-Term Growth (1) Per Last Twelve Months IMS Gross Revenues as of June 2017. (2) Includes expected Year 1 run-rate synergies. (3) In addition to the previously announced Impax standalone cost savings initiatives. Expanded Portfolio to Drive Growth  Creates 5th large

  9. Slide 9: Bryan Reasons, Chief Financial Officer

    9 Bryan Reasons Chief Financial Officer

  10. Slide 10: Generic Division 3Q 2017 Results

    10 Generic Division 3Q 2017 Results Refer to the GAAP to non-GAAP reconciliation tables in the appendix for a reconciliation of non-GAAP results. $ millions 3Q 2017 2Q 2017 Change 3Q/2Q 3Q 2016 Change 3Q/3Q GENERIC DIVISION Total Revenues $151.1 $150.9 0% $175.3 (14%) GAAP Gross Margin (2%) 28% -- (

  11. Slide 11: Specialty Pharma Division 3Q 2017 Results

    11 Specialty Pharma Division 3Q 2017 Results Refer to the GAAP to non-GAAP reconciliation tables in the appendix for a reconciliation of non-GAAP results. $ millions 3Q 2017 2Q 2017 Change 3Q/2Q 3Q 2016 Change 3Q/3Q SPECIALTY PHARMA DIVISION Total Revenues $55.3 $51.2 8% $52.6 5% GAAP Gross Margin 6

  12. Slide 12: Consolidated 3Q 2017 Results

    12 Consolidated 3Q 2017 Results Refer to the GAAP to non-GAAP reconciliation tables in the appendix for a reconciliation of non-GAAP results. $ millions, except per share amounts 3Q 2017 2Q 2017 Change 3Q/2Q 3Q 2016 Change 3Q/3Q EBITDA ($15.4) $16.6 (193%) ($247.9) 94% Adjusted EBITDA $45.6 $39.2 16

  13. Slide 13: Paul Bisaro, President & CEO

    13 Paul Bisaro President & CEO

  14. Slide 14: Updated 4Q17 Guidance Assumptions

    14 Updated 4Q17 Guidance Assumptions Factors Adversely Impacting 4Q • Delay in launch of generic Concerta® and generic Welchol® • Late approval of generic Renvela® and launch into a more competitive market • Inability of partner to supply generic Aggrenox® impacting royalty income • In addition, low

  15. Slide 15: Updated 2017 Financial Guidance

    15 Updated 2017 Financial Guidance * Excludes new cost savings initiatives as outlined on slide 7. The Company’s full year 2017 estimates are based on management’s current expectations, including with respect to prescription trends, pricing levels, inventory levels, and the anticipated timing of fut

  16. Slide 16: Path Forward

    16 Path Forward • Generics: Continuing internal R&D investment and external R&D license efforts • Specialty: Continuing focus on Movement Disorders pipeline and opportunistically in-license external opportunities Invest in Organic Growth • Maintain high level of Quality and Compliance • Achieve supe

  17. Slide 17: Q&A Session

    17 Third Quarter 2017 Results and Business Update Q&A Session November 9, 2017

  18. Slide 18: GAAP to Adjusted Results Reconciliation

    18 GAAP to Adjusted Results Reconciliation The following table reconciles total Company reported cost of revenues to adjusted cost of revenues, adjusted gross profit, adjusted gross margin, adjusted research and development expenses, and adjusted selling, general and administrative expenses. (Unaudi

  19. Slide 19: GAAP to Adjusted Net Income Reconciliation

    19 GAAP to Adjusted Net Income Reconciliation The following table reconciles reported net loss to adjusted net income. (Unaudited, In thousands, except per share and per share data) Refer to the Third Quarter 2017 Earnings Release for an explanation of adjusted items. The sum of the individual amoun

  20. Slide 20: GAAP to Adjusted EBITDA Reconciliation

    20 GAAP to Adjusted EBITDA Reconciliation Refer to the Third Quarter 2017 Earnings Release for an explanation of adjusted items. The sum of the individual amounts may not equal due to rounding. The following table reconciles reported net loss to adjusted EBITDA. (Unaudited, In thousands) September 3

  21. Slide 21: Generic Division GAAP to Adjusted Results Reconciliation

    21 Generic Division GAAP to Adjusted Results Reconciliation The following tables reconcile the Impax Generics Division reported cost of revenues and income (loss) from operations to adjusted cost of revenues, adjusted gross profit, adjusted gross margin and adjusted operating income. (Unaudited, In

  22. Slide 22: Specialty Pharma Division GAAP to Adjusted Results Reconciliation

    22 Specialty Pharma Division GAAP to Adjusted Results Reconciliation The following tables reconcile the Impax Specialty Pharma Division reported cost of revenues and income from operations to adjusted cost of revenues, adjusted gross profit, adjusted gross margin and adjusted income from operations.

Impax Laboratories — Q3 2017 Earnings Presentation on 6ix